Anthropic is embarking on a significant initiative to develop its own drugs, leveraging its AI model Claude Science to enhance lab research, similar to how Claude Code transformed programming. This effort will initially focus on neglected diseases, including rare genetic disorders and specific tropical conditions, which present clearer biological targets due to their single-gene basis. By deliberately selecting these overlooked areas, Anthropic aims to avoid direct competition with its pharmaceutical partners, with whom it collaborates closely to address research obstacles. The company’s commitment is underscored by its acquisition of Coefficient Bio and the hiring of AlphaFold researcher John Jumper, indicating a serious approach to integrating AI within the drug development landscape.

Novartis: Novartis is a major global pharmaceutical company engaged in the research, development, and commercialization of medicines. Its CEO Vas Narasimhan has joined Anthropic’s board, supplying direct industry expertise to inform AI product decisions in drug discovery and help align the technology with real-world research challenges.
Anthropic: Anthropic is an artificial intelligence company that develops large language models, including the Claude family. It is now building Claude Science to apply similar AI capabilities to laboratory research and drug discovery. The company is directing early efforts toward neglected diseases while leveraging acquisitions, key hires, and board input from pharmaceutical leaders to shape its approach.
John Jumper: John Jumper is a computational biologist known for leading development of AlphaFold, an AI system that predicts protein structures. He has been hired by Anthropic to advance its application of AI to biological problems, particularly in the context of its new drug-discovery initiatives.
Coefficient Bio: Coefficient Bio is a biotechnology company acquired by Anthropic to strengthen its capabilities in applying AI to biological research. The acquisition forms part of Anthropic’s broader strategy to build dedicated tools and expertise for drug discovery beyond general-purpose models.

{“Disease Focus”: “Anthropic is initially targeting neglected diseases, rare genetic disorders, and certain tropical conditions that often involve clearer single-gene biology.”, “Industry Alignment”: “Anthropic maintains close collaborations with major drugmakers and deliberately selects overlooked programs to avoid competing with pharmaceutical customers.”, “Strategic Commitment”: “Anthropic’s acquisition of Coefficient Bio and hiring of AlphaFold researcher John Jumper demonstrate a serious, integrated effort to advance AI in biology.”}

Anthropic is embarking on a significant initiative to develop its own drugs, leveraging its AI model Claude Science to enhance lab research, similar to how Claude Code transformed programming. This effort will initially focus on neglected diseases, including rare genetic disorders and specific tropical conditions, which present clearer biological targets due to their single-gene basis. By deliberately selecting these overlooked areas, Anthropic aims to avoid direct competition with its pharmaceutical partners, with whom it collaborates closely to address research obstacles. The company’s commitment is underscored by its acquisition of Coefficient Bio and the hiring of AlphaFold researcher John Jumper, indicating a serious approach to integrating AI within the drug development landscape.

Novartis: Novartis is a major global pharmaceutical company engaged in the research, development, and commercialization of medicines. Its CEO Vas Narasimhan has joined Anthropic’s board, supplying direct industry expertise to inform AI product decisions in drug discovery and help align the technology with real-world research challenges.
Anthropic: Anthropic is an artificial intelligence company that develops large language models, including the Claude family. It is now building Claude Science to apply similar AI capabilities to laboratory research and drug discovery. The company is directing early efforts toward neglected diseases while leveraging acquisitions, key hires, and board input from pharmaceutical leaders to shape its approach.
John Jumper: John Jumper is a computational biologist known for leading development of AlphaFold, an AI system that predicts protein structures. He has been hired by Anthropic to advance its application of AI to biological problems, particularly in the context of its new drug-discovery initiatives.
Coefficient Bio: Coefficient Bio is a biotechnology company acquired by Anthropic to strengthen its capabilities in applying AI to biological research. The acquisition forms part of Anthropic’s broader strategy to build dedicated tools and expertise for drug discovery beyond general-purpose models.

{“Disease Focus”: “Anthropic is initially targeting neglected diseases, rare genetic disorders, and certain tropical conditions that often involve clearer single-gene biology.”, “Industry Alignment”: “Anthropic maintains close collaborations with major drugmakers and deliberately selects overlooked programs to avoid competing with pharmaceutical customers.”, “Strategic Commitment”: “Anthropic’s acquisition of Coefficient Bio and hiring of AlphaFold researcher John Jumper demonstrate a serious, integrated effort to advance AI in biology.”}